Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy


I'm Interested

Trial ID: NCT06034197


The purpose of this study is to determine the safety and feasibility of VGT-309 for the visualization of colorectal tumors in real-time using near-infrared (NIR) fluorescence endoscopy. In addition, signatures of 50+ biomarkers will be evaluated in biopsies using CODEX multi-plexing.

Official Title

Pilot Open Label Study to Determine the Safety and Efficacy of Fluorescent Probe, VGT-309, to Identify Cancerous Colorectal Lesions During White-Light and Fluorescence Augmented Colonoscopy

Stanford Investigator(s)

Stephan Rogalla, M.D. PhD

Clinical Assistant Professor, Medicine - Gastroenterology & Hepatology

Erqi Pollom
Erqi Pollom

Associate Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery


Inclusion Criteria:

   - 1. Adult patients with histologically confirmed distal colorectal adenocarcinoma of
   any stage.

   2. Be willing and able to sign the informed consent and comply with study procedures.

   3. Are scheduled to undergo a SOC colonoscopy for restaging following
   radiochemotherapy or are scheduled to receive a SOC colonoscopy in the OR prior to
   resection 4. Have acceptable kidney and liver functions at study entry as evidenced

   a. ALT/AST < 1.5 times the upper limit of normal, b. Creatinine clearance (according
   to Cockcroft-Gault Equation) > 50 mL/min c. Total bilirubin < 1.5 times the upper
   limit of normal 5. Have an ECOG score of 0-2. 6. Be at least 18 years of age. 7.
   Female participants must be of non-childbearing potential, or, if of childbearing
   potential be non-pregnant or lactating and agree to use highly effective contraception
   from screening through 30 days after probe infusion 8. Male participants, if not
   surgically sterilized, and if engaging in sexual intercourse with a female partner of
   childbearing potential, must be willing to use highly effective contraception from
   screening through 30 days post-dose and agree not to donate semen during this waiting

   9. Highly effective contraception involves the use of a condom for the male, plus one
   of the following for the female:

      1. Oral, injectable, implantable, intravaginal, or transdermal hormonal
      contraceptives, or

      2. Intrauterine device or intrauterine hormone-releasing system. NOTE: Participants
      who abstain from heterosexual intercourse as their usual and preferred lifestyle,
      will not be required to use contraception as described above. They are required
      to maintain abstinence from screening through Day 30, AND Participants in a same
      sex relationship, must use a barrier form of contraception (e.g., condom,
      diaphragm) to protect against the transfer of the study drug in any bodily

      Exclusion Criteria:

   - 1. Pregnant or breastfeeding females 2. They have a known allergy or reaction to ICG,
   other radiographic contrast agents, or any component of VGT-309.

   3. Have congenital long QT syndrome or QTcF > 450ms (males) or >470ms (females) by
   history or at Screening ECG.

   4. They are prisoners, institutionalized individuals, or are unable to consent for

   5. Have any other comorbidity or habit that the Investigator believes will interfere
   with their ability to comply with and complete the study.


drug: VGT-309


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Joaquin Tabera

New Trial Alerts